Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep-Oct:54:62-64.
doi: 10.1016/j.genhosppsych.2018.05.007. Epub 2018 May 22.

Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor

R B Katz  1 , M Toprak  2 , S T Wilkinson  2 , G Sanacora  2 , R Ostroff  2
Affiliations

Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor

R B Katz et al. Gen Hosp Psychiatry. 2018 Sep-Oct.
No abstract available

Keywords: Depression; Ketamine; Monoamine oxidase inhibitor; Safety; Treatment-refractory.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

Dr. Sanacora has received consulting fees from Allergan, Alkermes, AstraZeneca, Avanier Pharmaceuticals, Axsome Therapeutics BioHaven Pharmaceuticals, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Hoffman La-Roche, Intra-Cellular Therapies, Janssen, Merck, Naurex, Navitor Pharmaceuticals, Novartis, Noven Pharmaceuticals, Otsuka, Praxis Therapeutics, Sage Pharmaceuticals, Servier Pharmaceuticals, Taisho Pharmaceuticals, Teva, Valeant, and Vistagen therapeutics over the last 36 months. He has also received additional research contracts from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Hoffman La-Roche, Merck, Naurex, and Servier over the last 36 months. Free medication was provided to GS for an NIH-sponsored study by Sanofi-Aventis. In addition, he holds shares in BioHaven Pharmaceuticals Holding Company and is a co-inventor on a patent ‘Glutamate agents in the treatment of mental disorders’ (Patent number: 8778979).

Dr. Wilkinson reports receiving research support from Janssen (administered through Yale) to conduct clinical trials as well as honoraria from Janssen.

The rest of the authors have no conflicts of interest.

References

    1. Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiat 2017. April 1;74(4):399–405. - PubMed
    1. Wilkinson ST, Toprak M, Turner MS, Levine SP, Katz RB, Sanacora G. A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. Am J Psychiatry 2017. July 1;174(7):695–6. - PMC - PubMed
    1. Bartova L, Vogl SE, Stamenkovic M, et al. Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: a report of two cases. Eur Neuropsychopharmacol 2015. November;25(11):2183–4. - PubMed
    1. Doyle DJ. Ketamine induction and monoamine oxidase inhibitors. J Clin Anesth 1990. Sep-Oct;2(5):324–5. - PubMed
    1. Wilkinson ST, Katz RB, Toprak M, et al. Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale Psychiatric Hospital. J Clin Psychiatry 2018. (In press). - PMC - PubMed

Publication types

MeSH terms